Drug-related challenges following primary total hip and knee arthroplasty
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Drug-related challenges following primary total hip and knee arthroplasty. / Sørensen, Anne Mette Skov; Nyeland, Martin Erik; Odgaard, Anders; Overgaard, Søren; Jimenez-Solem, Espen; Schelde, Astrid Blicher.
In: Basic & Clinical Pharmacology & Toxicology, Vol. 129, No. 2, 2021, p. 139-147.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Drug-related challenges following primary total hip and knee arthroplasty
AU - Sørensen, Anne Mette Skov
AU - Nyeland, Martin Erik
AU - Odgaard, Anders
AU - Overgaard, Søren
AU - Jimenez-Solem, Espen
AU - Schelde, Astrid Blicher
N1 - Publisher Copyright: © 2021 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
PY - 2021
Y1 - 2021
N2 - We aimed to characterize the in-hospital analgesic use among total hip or knee arthroplasty (THA or TKA) patients, and to identify possible drug-related challenges. We identified 15 263 patients operated with a THA or TKA between 1 January 2012 and 30 April 2016. The prevalence of analgesic users and patients with potential clinically relevant drug-drug interactions (DDIs), along with the prevalence of readmission among patients with vs. without a DDI, were calculated. A DDI was defined as the combination of (A) a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, and an non-steroidal anti-inflammatory Drug (NSAID); (B) warfarin and an NSAID; and (C) a benzodiazepine or a benzodiazepine-related drug and an opioid. The prevalence of analgesics administered in THA and TKA patients was 99.3% and 99.1% for paracetamol and 93.8% and 98.8% for opioids, respectively. The prevalence of patients who received interaction A, B or C was 8.4%, 2.5% and 40.7%, respectively. Patients with vs. without a DDI had a higher prevalence of 30-day readmission. In conclusion, most THA and TKA patients were administered paracetamol or opioids. The prevalence of 30-day readmission was higher in patients with than in patients without a potential clinically relevant DDI.
AB - We aimed to characterize the in-hospital analgesic use among total hip or knee arthroplasty (THA or TKA) patients, and to identify possible drug-related challenges. We identified 15 263 patients operated with a THA or TKA between 1 January 2012 and 30 April 2016. The prevalence of analgesic users and patients with potential clinically relevant drug-drug interactions (DDIs), along with the prevalence of readmission among patients with vs. without a DDI, were calculated. A DDI was defined as the combination of (A) a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, and an non-steroidal anti-inflammatory Drug (NSAID); (B) warfarin and an NSAID; and (C) a benzodiazepine or a benzodiazepine-related drug and an opioid. The prevalence of analgesics administered in THA and TKA patients was 99.3% and 99.1% for paracetamol and 93.8% and 98.8% for opioids, respectively. The prevalence of patients who received interaction A, B or C was 8.4%, 2.5% and 40.7%, respectively. Patients with vs. without a DDI had a higher prevalence of 30-day readmission. In conclusion, most THA and TKA patients were administered paracetamol or opioids. The prevalence of 30-day readmission was higher in patients with than in patients without a potential clinically relevant DDI.
KW - analgesic drugs
KW - drug interactions
KW - inappropriate prescriptions
KW - total hip replacement
KW - total knee replacement
U2 - 10.1111/bcpt.13616
DO - 10.1111/bcpt.13616
M3 - Journal article
C2 - 34014603
AN - SCOPUS:85107534173
VL - 129
SP - 139
EP - 147
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 2
ER -
ID: 273652749